【藥品性質提示】 #高警訊藥品 【藥品訊息】 Toujeo 胰島素筆 綠 450IU 衛教單張

糖尿病 (基礎胰島素) For the treatment of adult and pediatric patients(age over 6 years)<20201201> with type 1 diabetes mellitus, or adult patients with type 2 diabetes mellitus requiring basal (long-acting) insulin for the control of hyperglycemia.
#仿單變更2020

Insulin, Long-Acting
Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent.

Absorption:
1. Slow; upon injection into the subcutaneous tissue, microprecipitates form which allow small amounts of insulin glargine to release over time.
2. Onset of action: 6 hours; Duration: >24 hours
3. Time to peak, plasma: 12 to 16 hours following a single dose
Metabolism:
Partially metabolized in the subcutaneous depot at the carboxyl terminus of the B chain to form two active metabolites, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin)

1. Hypoglycemia
2. Hypersensitivity to insulin glargine or any of the excipients

Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.

Common:
Hypoglycaemia, injection site pain, rash
Use with caution in patients with diseases such as:
1. Coronary artery or donor cerebral vascular stenosis.
2. Proliferative retinopathy, especially not been treated with photocoagulation.<20201201>

Diabetes mellitus, type 1: SUBQ
1. Initial TDD: 0.4 to 0.5 units/kg/day in divided doses (0.2 to 0.4 units/kg/day may be considered to avoid hypoglycemia)
2. Usual TDD: 0.4 to 1 units/kg/day in divided doses
Diabetes mellitus, type 2: SUBQ
1. Initial: 10 units once daily or 0.1 to 0.2 units/kg once daily
2. HbA1c >8%, fasting plasma glucose >250 mg/dL, or insulin resistance: 0.2 to 0.3 units/kg/day (up to 15 to 20 units/day)
3. For persistently elevated fasting plasma glucose: Increase daily dose by 2 to 4 units or by 10% to 20% every 2 to 3 days
4. For hypoglycemia: Consider decreasing daily dose by 10% to 20%; for severe hypoglycemia requiring assistance from another person or blood glucose <40 mg/dL, consider reducing dose by 20% to 50%

There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Should be stored at 2-8℃, the opened vials or cartridges should be used within 28 days.